Please assess the completion status of the following clinical trial:

Trial Title: Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically confirmed adenocarcinoma of the breast~2. Female aged 20-75 years old at getting informed consent~3. HER2 negative disease (IHC 0/1+ or 2+ with FISH negative)~4. Documented estrogen receptor (ER) positive (\>=1% by IHC)~5. Inoperative locally advanced or metastatic breast cancer at enrolment~6. Performance status (ECOG): 0-1 at enrolment~7. Life expectancy of at least 3 months from enrolment~8. No prior systemic therapy for recurrent breast cancer (excluding hormone therapy)~9. No prior neo and/or adjuvant chemotherapy with taxane or adjuvant setting with a disease-free interval from completion of the taxane treatment to metastatic diagnosis of \>= 12 months~10. Patients with measurable lesion regarding with Response Evaluation Criteria in Solid Tumors(RECIST) criteria or who have evaluable lesion~11. Patients with only bone lesion will be acceptable if the osteolytic lesion has a measurable soft tissue component by MRI or CT~12. No influence on protocol treatment is considered in case prior therapy or examination.~13. Adequate following organ function within 2 weeks before starting treatment. The latest examination results should be adopted and blood transfusion or treatment of hematopoietic factor drugs is not allowed 2 weeks before examination.~    * Absolute neutrophil count \>= 1500 /mm3 or white blood cell(WBC) count \>= 3000 /mm3~   * Platelets \>=10 x 10000 /mm3~   * Hb \>= 9 g/dL~   * Total bilirubin \<= 1.5 mg/dL~   * aspartate aminotransferase(AST) and alanine aminotransferase(ALT) \<= 100 international unit(IU)/L~   * Serum creatinine \<= 1.5 mg/dL~   * Urine dipstick for proteinuria \<= 1+~14. Written informed consent signed by patients before completing any treatment related procedure~Exclusion Criteria:~1. Prior therapy with bevacizumab~2. Active infection requiring intrvenous antibiotics at enrollment or infection with active HBV and/or HCV.~3. Pregnancy, lactetion or in case of potentialy pregnancy women Not mind contraception in trial period.~4. Known hypersensitivity to bevacizumab or paclitaxel~5. History of hemoptysis (\>= 2.5mL of bright red blood per episord).~6. Use of disulfiram,cyanamide, carmofur or procarbazine Hydrochloride~7. Patients with CNS metastases (except for not symptomatic)~8. Persistent Grade \>= 2 sensory neuropathy at enrollment~9. Grade 3 \>= hypertension (\>= 2 use of antihypertensive drug)~10. Evidence with arterial thromboembolism (Cerebral infarction, Myocardial infarction) or history within 1 year prior to enrollment.~11. Evidence withvenous thromboembolism (deep vein thrombosis, pulmonary embolism) or history within 1 year prior to enrollment.~12. History of GI perforation and/or serious abdominal fistula within 1 year prior to enrollment~13. Cases that the investigator judged as inappropriate as the subject of this clinical study

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: ACTIVE_COMPARATOR): weekly paclitaxel + bevacizumab
- Arm B (Type: EXPERIMENTAL): endocrine therapy\* + bevacizumab then back to weekly paclitaxel + bevacizumab therapy~(\*Letrozole, Anastrozole, Exemestane, Fulvestrant, LHRH Analogs + Aromatase inhibitors.)

Based on this trial design, predict the completion outcome and termination type (if applicable).